Licbiotech

What Licbiotech does

Lincbiotech (legal entity LINCBIOTECH, S.L.), founded in 2017 as a spin-off of Fundación Ramón Domínguez and Conexiona, is a privately held Spanish biotechnology company headquartered at the Parque Tecnológico de Galicia in San Cibrao das Viñas, Ourense, with a registered office in Santiago de Compostela. The company employs 11–50 staff and develops diagnostic and therapeutic tools focused on highly prevalent neurological diseases, principally stroke and Alzheimer's disease and other tauopathies.

Its product portfolio is anchored by the Minerva ecosystem, a clinical decision support system (CDSS) for stroke patient management, extended through Minerva-segmentations (AI-driven multi-modality medical image segmentation across MRI, CT, PET, and X-ray with co-registration of up to 10 modalities), Minerva-knee (MRI knee analysis), Minerva-telemetry (leg radiography analysis), and the Minerva Marketplace, which distributes pre-trained image biomarker and segmentation models. Beyond software, the company markets an ELISA kit that detects misfolded tau proteins in cerebrospinal fluid for subclinical Alzheimer's diagnosis and is developing a pipeline of tau-targeting monoclonal antibodies through the ADMARKERS consortium. The company has also pursued adjacent diagnostics, including a CDTI-funded SARS-CoV-2 rapid test (2020) and the SERSBIOTech aquaculture pathogen detection project, and holds two pending European patent applications for proteasomal and lysosomal degraders.

Commercialization is organized around two channels: direct enterprise sales to hospitals, neurology departments, and clinical laboratories for Minerva CDSS and diagnostic kits (quote-based, no public pricing), and the Minerva Marketplace for pre-trained AI segmentation models distributed on a subscription basis. Revenue streams span subscription/Marketplace, one-time diagnostic kit licensing, and potential monoclonal antibody licensing/royalties. Public funding has come exclusively from non-dilutive Spanish and EU grants (IGAPE 2017, Spanish Ministry of Science 2019 for ADMARKERS, CDTI €195,758.03 in 2020); the company is participating in the EIC Corporate Partnership Programme and EIC Summit 2026, signaling intent to access European growth capital.

Name

Licbiotech

Legal name

LINCBIOTECH, S.L.

Website

https://lincbiotech.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Licbiotech is a privately held Spanish biotech that builds the Minerva AI imaging platform and tau-targeting diagnostics to support clinical management of stroke and Alzheimer's disease for hospitals, neurology departments, and clinical laboratories.

Ownership category

akta.pro rank

Product category

Neurological Diagnostics Software

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro industry

PRIMARYHLACALAG

AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)

Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT

SECONDARYHLACANAG

SaMD – Imaging & Signal Analysis (AI/ML)

Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

SECONDARYHLAAALAO

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)

Healthcare & Life Sciences/Biotechnology & Biologics/Diagnostics (Biotech-related)

SECONDARYHLAAAIAB

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

SECONDARYHDAAAEAH

Medical Imaging AI

Hardware, Technology & Telecom/Artificial Intelligence & Machine Learning/Computer Vision & Video Analytics

Keywords

• Clinical decision support
• Medical imaging software
• Neurological disease diagnostics
• Alzheimer's biomarker detection
• Stroke management platform

Headquarters

HQ city

San Ciprián De Viñas

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Medical Device Software (CDSS): Clinical decision support systems like Minerva for stroke patient management sold to healthcare providers.
2. Diagnostic Kits (ELISA): In-vitro diagnostic ELISA kits for detection of misfolded proteins in cerebrospinal fluid for Alzheimer's disease diagnosis.
3. AI Marketplace / Segmentation Models: Pre-trained segmentation models and image biomarker analysis tools available through Minerva marketplace ecosystem.
4. Monoclonal Antibodies: Next-generation monoclonal antibodies with applications in both diagnosis and treatment of neurological diseases.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Licbiotech develops and sells the Minerva AI ecosystem — a clinical decision support system (Minerva CDSS) for enhanced clinical management of stroke patients, automated medical image segmentation tools (Minerva-segmentations) supporting MRI, CT, PET, and X-ray, and the Minerva Marketplace for pre-trained segmentation models. Alongside software, the company sells in-vitro diagnostic products, including an ELISA kit to detect misfolded tau proteins in cerebrospinal fluid for early Alzheimer's diagnosis, and proprietary tau monoclonal antibodies for Alzheimer's and tauopathy diagnosis and treatment.

Product overview

Lincbiotech is a biotechnology startup developing innovative tools for diagnosis and treatment of neurological diseases. The company offers the Minerva ecosystem—a clinical decision support platform comprising Minerva (core CDSS for stroke), Minerva-segmentations (AI image segmentation), Minerva-knee (MRI knee analysis), and Minerva-telemetry (leg radiography analysis). Additionally, the company develops diagnostic products including an ELISA kit for Alzheimer's disease detection and tau monoclonal antibodies for therapeutic applications. The Minerva Marketplace provides pre-trained segmentation models and biomarkers. The company also maintains several R&D projects including ADMARKERS for Alzheimer's and BioTICfinder for COVID-19 diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

• Minerva: Clinical decision support system (CDSS) for enhanced clinical management of stroke patients. Also includes Minerva-segmentations (automated medical image segmentation), Minerva-knee, Minerva-telemetry, and a marketplace for image biomarker analysis and pre-trained segmentation models.
• ADMARKERS

Products and services

• Minerva Clinical Decision Support System (CDSS) Clinical decision support system providing useful insights to clinicians for enhanced clinical management of stroke patients, part of the broader Minerva AI ecosystem for medical imaging analysis. Intended for hospitals, neurology departments, and stroke units.
• Minerva-segmentations AI-powered medical image segmentation tool that automates model training on small sets of labeled examples (as few as 6 annotated scans), supporting MRI, CT, PET, and X-ray modalities and co-registered images with up to 10 mixed modalities. Designed for healthcare providers performing image biomarker analysis.
• Minerva Marketplace Marketplace within the Minerva ecosystem offering pre-trained segmentation models and image biomarker analysis tools for healthcare customers.
• ELISA Kit for Alzheimer's Disease Novel in-vitro ELISA diagnostic kit to detect misfolded tau proteins in cerebrospinal fluid (CSF), enabling Alzheimer's disease diagnosis even at the subclinical stage. For research institutions, pharmaceutical companies, and clinical laboratories working on Alzheimer's and tauopathies.
• Tau Monoclonal Antibodies Next-generation monoclonal antibodies with high affinity to several tau aberrant species, applicable in diagnosis and treatment of Alzheimer's disease and other tauopathies. Directed at pharmaceutical, biotech, and academic research partners via licensing.
• SARS-CoV-2 Rapid Diagnostic Kit Rapid diagnostic kit for SARS-CoV-2 using lateral flow chromatography technology. Developed with €195,758 partially reimbursable aid from CDTI under the 2020 emergency COVID-19 program.

Quantifiable outcome

• Minerva processed >1500 MRI knee studies and >2500 leg radiographies
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

Six partnerships are on record, tiered core and minor.

• ADMARKERS ConsortiumcoreStrategic or Co-development PartnerCollaborative R&D project focused on early Alzheimer's markers using advanced imaging and in-vitro diagnostics. The project bases its approach on the importance of tau oligomers in early AD pathophysiology.
• BioTICfinder ConsortiumcoreStrategic or Co-development PartnerMulti-partner consortium developing diagnostic and therapeutic solutions against SARS-CoV-2 using aptamers, molecular biology, and digital technologies. Partners include ITELSIS, GMA, SIXTEMA, MESTRELAB RESEARCH, University of Vigo, and CETGA.
• SERSBIOTech ConsortiumminorStrategic or Co-development PartnerIoT system for automatic detection of pathogens in water using AI, biotechnology, and nano SERS technology for aquaculture farms. Partners include ITELSIS (coordinator), GMA, SIXTEMA, MESTRELAB RESEARCH, University of Vigo, and CETGA. Funded by GAIN Conecta Hubs program.
• Fundación Ramón Domínguez (FRD)coreStrategic or Co-development PartnerLincbiotech is a spin-off biotechnology company of Fundación Ramón Domínguez and Conexiona, specialized in developing and commercializing healthcare solutions for neurological disease diagnosis, prevention, and treatment.
• Redsys Servicios de Procesamiento, S.L.minorOthersPayment gateway provider for processing e-commerce transactions on the Lincbiotech website. Based in Madrid, Spain.
• PayPal (Europe) S.à.r.l. et Cie, S.C.A.minorOthersPayment processor for e-commerce transactions on the Lincbiotech website.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat4 records

Key highlights6 records

Customer concentration

• Xx.com/lincbiotech
• LinkedInlinkedin.com/company/lincbiotech

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Licbiotech